Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Polycystic Ovary Syndrome 2Insulin Resistance 1

Interventions

Metformin 152Clomiphene 52Letrozole 41Inositol 35Folic Acid 18Progesterone 17Exercise 17Ethinyl Estradiol 13Estradiol 13Chorionic Gonadotropin 13Caloric Restriction 13drospirenone and ethinyl estradiol combination 12Contraceptives, Oral 12cetrorelix 11Pioglitazone 10High-Intensity Interval Training 10Cholecalciferol 10Triptorelin Pamoate 9Tablets 9Spironolactone 9Menotropins 8Diet 8Vitamin D 7Thioctic Acid 7Surveys and Questionnaires 7Liraglutide 7Gonadotropins 7Acupuncture Therapy 7follitropin alfa 6drospirenone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Polycystic Ovary Syndrome × DLBS3233 × Clear all
NCT01999686 2019-05-28

POSITIF

Dexa Medica Group

Phase 3 Completed
186 enrolled

Insulin Resistance, Polycystic Ovary Syndrome

NCT01733459 2018-07-26

Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

Dexa Medica Group

Phase 3 Completed
124 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡